Hot Features
Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
Oncternal Therapeutics Inc is a clinical-stage oncology company developing first-in-class, novel therapies that target a broad spectrum of cancers with a large unmet medical need. The Company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to ROR1 (Receptor-tyro... Oncternal Therapeutics Inc is a clinical-stage oncology company developing first-in-class, novel therapies that target a broad spectrum of cancers with a large unmet medical need. The Company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to ROR1 (Receptor-tyrosine kinase-like Orphan Receptor 1), and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins. The Company is also developing ONCT-808, a CAR-T (chimeric antigen receptor T-cells) product candidate that targets ROR1 and ONCT-534, a dual-action androgen receptor inhibitor product candidate for the treatment of castration-resistant prostate and other androgen receptor-driven cancers. Show more
SAN DIEGO, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT) (the “Company”) today announced updated data from its Phase 1/2 Study of ONCT-534 for the treatment of...
SAN DIEGO, Sept. 12, 2024 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT) (the “Company”) today announced its decision to discontinue its clinical trials evaluating ONCT-534, its...
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.3857 | -35.712962963 | 1.08 | 1.2 | 0.62 | 316333 | 0.74669967 | CS |
| 4 | -0.8597 | -55.3217503218 | 1.554 | 1.7353 | 0.62 | 152428 | 1.03085572 | CS |
| 12 | -3.3357 | -82.7717121588 | 4.03 | 4.4599 | 0.62 | 126809 | 1.40682523 | CS |
| 26 | -8.7857 | -92.6761603376 | 9.48 | 9.88 | 0.62 | 63654 | 1.72094483 | CS |
| 52 | -6.8057 | -90.7426666667 | 7.5 | 13.14 | 0.62 | 84831 | 6.22523311 | CS |
| 156 | -61.5057 | -98.8837620579 | 62.2 | 62.2 | 0.62 | 321464 | 22.59843575 | CS |
| 260 | -119.7057 | -99.4233388704 | 120.4 | 211.2 | 0.62 | 657040 | 75.58961578 | CS |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
Premium
